November 11, 2010
Tetraphase Announces Presentation at Lazard Capital Markets and Piper Jaffray & Co. Healthcare Conferences

October 12, 2010
Tetraphase Pharmaceuticals Names Garen Bohlin to Board of Directors to Advance Strategic Interests and Broaden Corporate Development Goals

October 1, 2010
Tetraphase Announces Presentation at BIO Investor Forum and Panel Discussion at Citi's 5th Annual Biotech Day

September 16, 2010
Tetraphase to Present at UBS Global Life Sciences Conference

September 15, 2010
Tetraphase Named as One of the FierceBiotech "Fierce15"

September 15, 2010
Tetraphase Demonstrates that Novel Antibiotic, TP-434, is Effective Against Gram-negative Multidrug-resistant Pathogens in Preclinical Studies

September 13, 2010
Tetraphase Presents New Clinical and Preclinical Data for Novel Antibiotic TP-434 at 2010 ICAAC

September 8, 2010
Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC

June 1, 2010
Tetraphase Closes $45 Million Series C Financing. Company to advance novel antibiotics into clinical development to address serious drug-resistant, gram-negative infections

April 29, 2010
Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention